Alpine Immune Sciences: Going Strong But For How Long?
Suriphon Singha/iStock via Getty Images A little less than a year ago I wrote an article about Alpine Immune Sciences (NASDAQ:ALPN), explaining the reasons why I still believed in the company, after the ditching of their main trials, based on the death of their second patient. Since then, the stock has run nearly 150%. Too bad I got out around the $11 price point. Recently, the company reported their financial results for the second quarter of 2023, showing a loss of $0.27 per
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.